Drug Detail

Information about Cobimetinib

Generic Name	Cobimetinib
IND	GDC-0973
Brand Name (US)
Manufacturer	Genentech/Exelixis
Drug Type	MEK inhibitor
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	MEK inhibitor

Also called XL518.
Description GDC-0973, a selective inhibitor of MEK, also known as mitogen activated protein kinase kinase (MAPKK), is a key component of the RAS/RAF/MEK/ERK pathway, which is frequently activated in human tumors. Inappropriate activation of the MEK/ERK pathway promotes cell growth in the absence of exogenous growth factors.

Development Status:
A Phase I clinical trial evaluating GDC-0973 for solid tumors, a Phase Ib clinical trial in combination with GDC-0941, a PI3 Kinase Inhibitor, for solid tumors and a Phase Ib clinical trial in combination with vemurafenib, a BRAF inhibitor, for metastatic melanoma are ongoing.

GDC-0973 is being developed in a collaboration of Genentech and Exelixis.